Epigenetic Mechanisms Involved in Inflammaging-Associated Hypertension.

Autor: Simão VA; Department of Structural and Functional Biology, Institute of Biosciences, UNESP - São Paulo State University, Zip Code: 510, P.O Box: 18618-689, Botucatu, São Paulo, Brazil., Ferder L; Universidad Maimónides, Ciudad Autónoma de Buenos Aires, Argentina., Manucha W; Laboratorio de Farmacología Experimental Básica Y Traslacional. Área de Farmacología, Departamento de Patología, Facultad de Ciencias Médicas, Universidad Nacional de Cuyo, Mendoza, Argentina.; Instituto de Medicina Y Biología Experimental de Cuyo, Consejo Nacional de Investigación Científica Y Tecnológica (IMBECU-CONICET), Mendoza, Argentina., Chuffa LGA; Department of Structural and Functional Biology, Institute of Biosciences, UNESP - São Paulo State University, Zip Code: 510, P.O Box: 18618-689, Botucatu, São Paulo, Brazil. luiz-gustavo.chuffa@unesp.br.
Jazyk: angličtina
Zdroj: Current hypertension reports [Curr Hypertens Rep] 2022 Nov; Vol. 24 (11), pp. 547-562. Date of Electronic Publication: 2022 Jul 07.
DOI: 10.1007/s11906-022-01214-4
Abstrakt: Purpose of Review: This review summarizes the involvement of inflammaging in vascular damage with focus on the epigenetic mechanisms by which inflammaging-induced hypertension is triggered.
Recent Findings: Inflammaging in hypertension is a complex condition associated with the production of inflammatory mediators by the immune cells, enhancement of oxidative stress, and tissue remodeling in vascular smooth muscle cells and endothelial cells. Cellular processes are numerous, including inflammasome assembly and cell senescence which may involve mitochondrial dysfunction, autophagy, DNA damage response, dysbiosis, and many others. More recently, a series of noncoding RNAs, mainly microRNAs, have been described as possessing epigenetic actions on the regulation of inflammasome-related hypertension, emerging as a promising therapeutic strategy. Although there are a variety of pharmacological agents that effectively regulate inflammaging-related hypertension, a deeper understanding of the epigenetic events behind the control of vessel deterioration is needed for the treatment or even to prevent the disease onset.
(© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: